{"log_id": 8236970368736154324, "direction": 0, "words_result_num": 29, "words_result": [{"probability": {"variance": 0, "average": 0.999605, "min": 0.998778}, "location": {"width": 144, "top": 174, "height": 29, "left": 93}, "words": "儿童发育迟缓"}, {"probability": {"variance": 7e-06, "average": 0.998638, "min": 0.988768}, "location": {"width": 921, "top": 205, "height": 47, "left": 139}, "words": "伊马替尼可能影响儿童的身材,特别是青春前期儿童。尽管在治疗CML时生长发育迟"}, {"probability": {"variance": 4e-06, "average": 0.998993, "min": 0.991126}, "location": {"width": 896, "top": 252, "height": 50, "left": 92}, "words": "缓病例的信息有限,但儿童生长发育迟缓和伊马替尼治疗之间的因果关系不能被排除"}, {"probability": {"variance": 1.4e-05, "average": 0.99872, "min": 0.985643}, "location": {"width": 321, "top": 313, "height": 36, "left": 92}, "words": "严重的呼吸系统药物不良反应"}, {"probability": {"variance": 2e-06, "average": 0.999333, "min": 0.991075}, "location": {"width": 900, "top": 351, "height": 46, "left": 142}, "words": "使用伊马替尼治疗已观察到严重的呼吸系统事件,有时是致命的,包括急性呼吸衰竭"}, {"probability": {"variance": 4e-06, "average": 0.999129, "min": 0.986685}, "location": {"width": 970, "top": 400, "height": 46, "left": 94}, "words": "肺动脉高压,肺间质疾病和肺纤维化。在许多病例中,先前存在心脏或肺部疾病可能与诸多"}, {"probability": {"variance": 2e-06, "average": 0.999199, "min": 0.99575}, "location": {"width": 243, "top": 459, "height": 32, "left": 98}, "words": "严重呼吸系统事件有关"}, {"probability": {"variance": 0, "average": 0.999639, "min": 0.999078}, "location": {"width": 170, "top": 509, "height": 30, "left": 97}, "words": "实验室检查异常"}, {"probability": {"variance": 0, "average": 0.999573, "min": 0.998615}, "location": {"width": 98, "top": 558, "height": 28, "left": 97}, "words": "血液系统"}, {"probability": {"variance": 2e-05, "average": 0.998353, "min": 0.973538}, "location": {"width": 893, "top": 589, "height": 46, "left": 148}, "words": "CML患者中,所有研究均报告有血细胞减少,尤其是中性粒细胞和血小板减少"}, {"probability": {"variance": 0.000493, "average": 0.994719, "min": 0.850914}, "location": {"width": 968, "top": 636, "height": 48, "left": 100}, "words": "以>750mg/日的大剂量时发生率较高(I期研究),然而血细胞减少的发生率也明显取决于疾"}, {"probability": {"variance": 2e-05, "average": 0.997671, "min": 0.974101}, "location": {"width": 971, "top": 685, "height": 47, "left": 98}, "words": "病分期。新诊断CML患者血细胞减少的发生率要小于其他CML患者。3或4度的中性粒细"}, {"probability": {"variance": 0.005149, "average": 0.978577, "min": 0.626164}, "location": {"width": 970, "top": 734, "height": 46, "left": 99}, "words": "胞减少(ANC<1.0×10°L)和血小板减少(血小板计数<50×10/L),在急变期和加速期的发"}, {"probability": {"variance": 0.003919, "average": 0.97777, "min": 0.689776}, "location": {"width": 971, "top": 782, "height": 46, "left": 100}, "words": "生率(中性粒细胞减少和血小板减少的发生率分别为59%~61%、44%~63%)较新诊断慢性期"}, {"probability": {"variance": 0.00057, "average": 0.994437, "min": 0.839733}, "location": {"width": 970, "top": 829, "height": 47, "left": 101}, "words": "患者(中性粒细胞减少发生率为16.7%,血小板减少发生率为8.9%)高4和6倍。新诊断慢"}, {"probability": {"variance": 0.006785, "average": 0.976508, "min": 0.5683}, "location": {"width": 968, "top": 878, "height": 44, "left": 101}, "words": "性期CML患者中4度中性粒细胞减少(ANC<1.0×103/L)和血小板减少(血小板计数<50×"}, {"probability": {"variance": 0.012762, "average": 0.969618, "min": 0.431186}, "location": {"width": 968, "top": 925, "height": 48, "left": 104}, "words": "0°)的发生率分别为3.6%和<1%中性粒细胞和血小板减少发生的中位数持续时间分别为"}, {"probability": {"variance": 2e-06, "average": 0.998848, "min": 0.994717}, "location": {"width": 968, "top": 974, "height": 47, "left": 104}, "words": "2~3周和3~4周。对于这类事件,一般可通过降低剂量或暂停用药而缓解,仅个别病例需为"}, {"probability": {"variance": 1e-05, "average": 0.998277, "min": 0.986495}, "location": {"width": 970, "top": 1022, "height": 47, "left": 104}, "words": "此而长期停药。儿童CML患者最常见毒性反应为3或4度血细胞减少,包括中性粒细胞减"}, {"probability": {"variance": 9.7e-05, "average": 0.995626, "min": 0.959569}, "location": {"width": 841, "top": 1061, "height": 64, "left": 106}, "words": "少、血小板减少和贫血。这些毒性反应通常发生在首次治疗的前几个月"}, {"probability": {"variance": 0.00737, "average": 0.981793, "min": 0.432244}, "location": {"width": 919, "top": 1117, "height": 46, "left": 153}, "words": "在GIST患者,出现3级和4级贫血的发生率分别为5.4%和07%,这些患者中至少有一"}, {"probability": {"variance": 0.005551, "average": 0.98568, "min": 0.502872}, "location": {"width": 961, "top": 1165, "height": 47, "left": 107}, "words": "部分是与胃肠道或肿瘤内出血有关。3级和4级中性粒细胞减少的发生率分别为7.5%和2.7%"}, {"probability": {"variance": 9e-06, "average": 0.998612, "min": 0.982747}, "location": {"width": 970, "top": 1213, "height": 49, "left": 107}, "words": "而3级血小板减少的发生率为0.7%,没有患者发生4级血小板减少。全血细胞和中性粒细胞"}, {"probability": {"variance": 2e-06, "average": 0.999236, "min": 0.992711}, "location": {"width": 704, "top": 1265, "height": 46, "left": 108}, "words": "计数降低主要发生在治疗的最初6周,以后细胞计数保持相对稳定"}, {"probability": {"variance": 0, "average": 0.998458, "min": 0.997674}, "location": {"width": 97, "top": 1328, "height": 29, "left": 111}, "words": "生化检查"}, {"probability": {"variance": 3.9e-05, "average": 0.997487, "min": 0.97047}, "location": {"width": 920, "top": 1357, "height": 47, "left": 160}, "words": "CML患者显著的转氨酶升高(<5%)或胆红素升高(<1%)不常见,其能够通过减量或"}, {"probability": {"variance": 1e-06, "average": 0.998936, "min": 0.995551}, "location": {"width": 972, "top": 1405, "height": 47, "left": 109}, "words": "停药(中位持续时间约为一周)来缓解,只有不到1%的患者因肝功能实验室检查异常而长期"}, {"probability": {"variance": 0.000444, "average": 0.98986, "min": 0.876075}, "location": {"width": 970, "top": 1452, "height": 48, "left": 110}, "words": "停药。GIST患者(B22研究)中,6.8%的患者出现3或4级血清丙氨酸氨基转移酶(ALT)"}, {"probability": {"variance": 0.000109, "average": 0.997102, "min": 0.930696}, "location": {"width": 969, "top": 1500, "height": 49, "left": 111}, "words": "升高,4.8%出现3或4级血清天门冬氨酸氨基转移酶(AST)升高。胆红素升高的发生率小"}], "language": 3}